Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5435-5441

  Rajendran, Joseph G ^a,e   Schwartz, David L ^a,b,d   O'Sullivan, Janet ^c   Peterson, Lanell M ^a   Ng, Patrick ^a   Scharnhorst, Jeffrey ^a   Grierson, John R ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBOPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL HYPOXIA; CONTROLLED STUDY; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; LARYNX TUMOR; MAJOR CLINICAL STUDY; MAXILLA SINUS TUMOR; MOUTH TUMOR; OROPHARYNX TUMOR; PAROTID GLAND TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

AGED; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; MISONIDAZOLE; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS;

EID: 33749344131     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1773     Document Type: Article

References (38)

1. Adam M, Gabalski EC, Bloch DA, et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck 1999;21:146-53.
2. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28.
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
4. Hockel M, Schlenger K, Knoop C, Vaupel P. Oxygenation of carcinoma of the uterine cervix: evaluation by computerized oxygen tension measurements. Cancer Res 1991;51:6098-102.
5. Rajendran JG, Wilson DC, Conrad EU, et al. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704.
6. 2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 2001;177:462-8.
7. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56.
8. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
9. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000;83:354-9.
10. Koh W-J, Griffin TW, Rasey JS, Laramore GE. Positron emission tomography. A new tool for characterization of malignant disease and selection of therapy. Acta Oncol 1994;33:323-7.
11. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with (60)Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8.
12. Rajendran JG, Krohn KA. Imaging Tumor Hypoxia. In: Bailey DL, Townsend DW, Valk PE, Maisey MN, editors. Positron emission tomography, principles and practice. London: Springer-Verlag: 2002.
13. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-54.
14. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91.
15. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
16. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res 1990;122:301-8.
17. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984;54:2441-9.
18. Rajendran JG, Peterson LM, Schwartz DL, et al. [F-18] FMISO PET hypoxia imaging in head and neck cancer: heterogeneity in hypoxia-primary tumor vs lymph nodal metastases. J Nucl Med 2002;43:73P.
19. Rajendran JG, Ng P, Peterson LM, et al. F-18 FMISO PET tumor hypoxia imaging: investigating the tumor volume-hypoxia connection. J Nucl Med 2003;44 1340-76P,
20. Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [(18)F]fluoromisonidazole and [(18)F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52.
21. Lewellen TK, Kohlmyer SG, Miyaoka RS, Schubert SF, Stearns CW, Investigation of the count rate performance of the General Electric Advance positron emission tomograph. IEEE Trans Nucl Sci 1995;42 1051-7.
22. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner J Nucl Med 1994;35:1398-406.
23. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
24. Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. Radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343-50.
25. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.
26. Neter J, Hunter MH, Nachtscheim CJ, Wasserman W. Applied linear statistical models. 4th ed. Chicago: McGraw-Hill/Irwin; 1996. p.376.
27. Kumar P. Tumor hypoxia and anemia: impact on the efficacy of radiation therapy. Semin Hematol 2000;37 4-8.
28. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:537-49
29. Stadler P, Becker A, Feldmann HJ, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999;44:749-54.
30. Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, et al. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys 2004;59:1018-26.
31. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941-6.
32. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43:169-87.
33. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-50.
34. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42.
35. Rajendran JG, Muzi M, Peterson LM, et al. Analyzing the results of [F-18] FMISO PET hypoxia imaging: what is the best way to quantify hypoxia? J Nucl Med 2002;43:102P.
36. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157-62.
37. Peters LJ. Targeting hypoxia in head and neck cancer. Acta Oncol 2001;40:937-40.
38. Rajendran JG, Meyer J, Schwartz DL, et al. Imaging with F-18 FMISO-PET permits hypoxia directed radiotherapy dose escalation for head and neck cancer. J Nucl Med 2003;44:415, 127P.